Skip to main content

Theratechnologies(TH-T)
TSX

Today's Change
Real-Time Last Update
Day Low2.00
Day High2.03
Open:2.00
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
GlobeNewswire
Theratechnologies Announces Update on its Preclinical Oncology Research Program
GlobeNewswire
Theratechnologies Appoints Jordan Zwick to its Board of Directors
GlobeNewswire
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
GlobeNewswire
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
GlobeNewswire
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
GlobeNewswire
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
Baystreet
Stocks in play: Theratechnologies Inc.
GlobeNewswire
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
GlobeNewswire
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
GlobeNewswire
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
GlobeNewswire
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
GlobeNewswire
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
GlobeNewswire
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
Baystreet
Stocks in play: Theratechnologies Inc.
GlobeNewswire
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award

Profile

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.